STAAR Surgical (NASDAQ:STAA) Major Shareholder Purchases $2,155,022.94 in Stock

STAAR Surgical (NASDAQ:STAA - Get Free Report) major shareholder Broadwood Partners, L.P. bought 138,054 shares of the business's stock in a transaction that occurred on Monday, April 7th. The stock was purchased at an average price of $15.61 per share, for a total transaction of $2,155,022.94. Following the completion of the acquisition, the insider now owns 13,332,264 shares in the company, valued at $208,116,641.04. This represents a 1.05 % increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. Major shareholders that own more than 10% of a company's shares are required to disclose their transactions with the SEC.

Broadwood Partners, L.P. also recently made the following trade(s):

• On Wednesday, April 9th, Broadwood Partners, L.P. acquired 8,200 shares of STAAR Surgical stock. The shares were acquired at an average price of $15.08 per share, with a total value of $123,656.00.
• On Friday, April 4th, Broadwood Partners, L.P. bought 497,631 shares of STAAR Surgical stock. The stock was acquired at an average price of $15.91 per share, for a total transaction of $7,917,309.21.
• On Wednesday, April 2nd, Broadwood Partners, L.P. purchased 31,780 shares of STAAR Surgical stock. The shares were bought at an average price of $17.43 per share, with a total value of $553,925.40.
• On Monday, March 31st, Broadwood Partners, L.P. acquired 22,189 shares of STAAR Surgical stock. The stock was bought at an average cost of $17.46 per share, with a total value of $387,419.94.
• On Thursday, March 27th, Broadwood Partners, L.P. purchased 3,620 shares of STAAR Surgical stock. The shares were bought at an average price of $17.48 per share, with a total value of $63,277.60.
• On Tuesday, March 25th, Broadwood Partners, L.P. acquired 34,296 shares of STAAR Surgical stock. The shares were bought at an average price of $17.44 per share, for a total transaction of $598,122.24.
• On Thursday, March 20th, Broadwood Partners, L.P. bought 108,720 shares of STAAR Surgical stock. The stock was purchased at an average price of $17.96 per share, with a total value of $1,952,611.20.
• On Tuesday, March 18th, Broadwood Partners, L.P. purchased 93,124 shares of STAAR Surgical stock. The shares were purchased at an average cost of $17.54 per share, for a total transaction of $1,633,394.96.
• On Monday, March 3rd, Broadwood Partners, L.P. acquired 249,503 shares of STAAR Surgical stock. The stock was purchased at an average cost of $16.64 per share, with a total value of $4,151,729.92.
• On Thursday, February 27th, Broadwood Partners, L.P. bought 259,316 shares of STAAR Surgical stock. The shares were purchased at an average cost of $17.05 per share, for a total transaction of $4,421,337.80.

STAAR Surgical Trading Up 7.8 %

Shares of STAA stock traded up $1.22 during trading on Friday, reaching $16.79. 1,170,915 shares of the company's stock traded hands, compared to its average volume of 790,156. The firm's 50-day moving average is $17.66 and its 200 day moving average is $24.00. The company has a market capitalization of $828.17 million, a P/E ratio of -40.95 and a beta of 0.75. STAAR Surgical has a 1 year low of $13.50 and a 1 year high of $51.34.

Remove Ads

Analysts Set New Price Targets

A number of analysts recently commented on the company. Piper Sandler decreased their price target on STAAR Surgical from $40.00 to $16.00 and set a "neutral" rating for the company in a research report on Wednesday, February 12th. StockNews.com lowered STAAR Surgical from a "hold" rating to a "sell" rating in a research report on Thursday, February 13th. William Blair downgraded shares of STAAR Surgical from an "outperform" rating to a "market perform" rating in a report on Wednesday, February 12th. Stifel Nicolaus reduced their price target on shares of STAAR Surgical from $38.00 to $20.00 and set a "buy" rating for the company in a research report on Wednesday, February 12th. Finally, Canaccord Genuity Group lowered their price objective on shares of STAAR Surgical from $28.00 to $17.00 and set a "hold" rating on the stock in a research report on Thursday, February 13th. Two investment analysts have rated the stock with a sell rating, eight have given a hold rating and one has assigned a buy rating to the company's stock. Based on data from MarketBeat.com, the stock has an average rating of "Hold" and an average price target of $25.29.

Institutional Investors Weigh In On STAAR Surgical

Several institutional investors have recently made changes to their positions in STAA. Quarry LP bought a new stake in shares of STAAR Surgical during the 3rd quarter valued at $50,000. KLP Kapitalforvaltning AS bought a new stake in shares of STAAR Surgical during the fourth quarter valued at about $180,000. GAMMA Investing LLC lifted its holdings in shares of STAAR Surgical by 4,086.0% in the first quarter. GAMMA Investing LLC now owns 14,651 shares of the medical instruments supplier's stock worth $258,000 after buying an additional 14,301 shares in the last quarter. Bridgefront Capital LLC boosted its position in shares of STAAR Surgical by 27.2% in the fourth quarter. Bridgefront Capital LLC now owns 10,792 shares of the medical instruments supplier's stock valued at $262,000 after acquiring an additional 2,306 shares during the period. Finally, FMR LLC grew its stake in STAAR Surgical by 79.3% during the third quarter. FMR LLC now owns 7,092 shares of the medical instruments supplier's stock valued at $263,000 after acquiring an additional 3,136 shares in the last quarter. Hedge funds and other institutional investors own 96.70% of the company's stock.

About STAAR Surgical

STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and companion delivery systems to deliver the lenses into the eye. The company provides implantable Collamer lens product family (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia.